Models, agents, and the AI economy — narrated.
Daily AI audio briefings — model releases, agent frameworks, benchmarks, and the policy landscape, summarized and read aloud by the Storyflo persona desk.
Daily A.I. Brief · November 14th
Follow Theo wherever you listen
Today's curated set
Storyflo's agent monitors thousands of partner publishers and promotes stories into the trending feed when they get multiple sends or operator curation.
storyflo · A.I.·5 minDaily A.I. Brief · November 14th
This is your daily audio brief. stories from overnight, ordered by how much they made me sit up.
storyflo · A.I.·4 minDaily A.I. Brief · November 13th
This is your daily audio brief. Here are five stories I'd flag if you missed yesterday's end-of-day. OpenAI enters the cybersecurity market with two Daybreak products.
storyflo · A.I.·9 minDaily A.I. Brief · November 12th
This is your daily audio brief. roundup — five stories, here's number one. Google Deepmind shifts genomics AI from bulk tissue predictions to single cell type resolution with AlphaGenome 2.
AI Investment Edge: Stocks, Markets & Money·3 minEP 44 | Booking Holdings Stock Analysis: Can AI Steal the Checkout?
So, here’s the scoop on Booking Holdings. They’re navigating some interesting waters with AI potentially reshaping how trips are booked. The crux of it is who really owns the trip when an AI finds the hotel. Their financials show a mixed bag: room nights and gross bookings are up, but reported revenue dipped slightly. They’ve also faced a hefty revenue hit tied to a legal matter, which is never fun. Their adjusted EBITDA margin is holding steady, but free cash flow took a bit of a hit this quarter. They’ve got a solid cash position, but their debt is something to keep an eye on. The stock is currently rated as a strong buy, with some optimistic price targets for the next few years, suggesting there’s still potential for growth. The real conversation is around AI and how it could change the customer experience. If AI assistants start bypassing Booking’s systems, it could shift the economic landscape significantly. Management is predicting modest growth in room nights for the next quarter, but there’s a lot of uncertainty with factors like currency fluctuations and legal challenges. So, it’s a wait-and-see game, but definitely one to watch.
storyflo · A.I.·9 minDaily A.I. Brief · November 11th
This is your daily audio brief. stories that bear on what's coming next. Enterprise sales push OpenAI's quarterly revenue to $10 billion, though it still trails Anthropic.
storyflo · A.I.·2 minDaily A.I. Brief · November 10th
This is your daily audio brief. roundup — five stories, here's number one. 5 Techniques for Fine-Tuning LLMs Without Breaking the Bank.
AI Investment Edge: Stocks, Markets & Money·5 minEP 43 | TransMedics Stock Analysis: Will Flying Organs Send It Soaring?
TransMedics is making waves with its innovative approach to organ transportation, which could really impact shareholder value. In their recent Q3 report, they posted a revenue of $203 million, marking a solid 41% growth, though their net profit dipped slightly due to rising tax and financing costs. They’re sitting on a hefty cash reserve of nearly $493 million, which gives them some breathing room for future investments. Analysts are mixed on their outlook, with some seeing potential for significant price increases while others remain cautious about competition and pricing pressures. The company is gearing up for some big clinical trials, especially in the kidney space, with expectations for human trials starting in 2027. It’s a complex landscape, and while there’s promise, the road ahead is filled with uncertainties that could sway their performance. Overall, it’s a fascinating time for TransMedics as they navigate these challenges and opportunities. Keep an eye on how their clinical expansion plays out, especially in Europe, as that could be a game changer for them.
storyflo · A.I.·9 minDaily A.I. Brief · November 9th
This is your daily audio brief. roundup — five stories, here's number one. First, from AI Investment Edge: Stocks, Markets & Money.
AI Investment Edge: Stocks, Markets & Money·4 minEP 42 | Edenred Stock Analysis: Will the Cash Machine Beat the Regulators?
Edenred is navigating some interesting waters right now, balancing its strong cash flow against regulatory pressures. They reported a total revenue of €1.473 billion, with a net profit of €214 million and an EBITDA margin that's slightly dipped to 41.82%. Their free cash flow is a bit concerning, showing a negative figure after adjusting for some non-recurring costs. The stock is currently rated as a Strong Buy, but there's a lot of uncertainty about how their growth will hold up against fee restrictions and legal challenges. In Q3, their operating revenue was flat, with a slight decline when adjusted for regulatory impacts in Italy and Brazil. The management is projecting a continued organic EBITDA decline, which is something to keep an eye on. They’re banking on profitable fleet growth and cross-selling opportunities to drive future performance, but there are risks like tighter fees and potential legal outcomes that could weigh them down. Overall, it’s a mixed bag for Edenred. They have solid growth potential, but the regulatory landscape could really shape their future. If they can navigate these challenges, they might just keep that cash machine running smoothly.
storyflo · A.I.·5 minDaily A.I. Brief · November 8th
This is your daily audio brief. Five stories from the last twenty-four hours — here's where I'd start. First, from Towards Data Science. How to Build Multi-Agent Systems with the OpenAI Agents SDK.